The FTC on Thursday voted, 3-0, “to issue a statement cautioning against reliance on prior advocacy statements and studies related to pharmacy benefit managers (PBM) that no longer reflect current market realities.”
FTC: “The statement is a response to PBMs' continued reliance on older FTC advocacy materials”
“S. 1038 and S. 2052 are vital for real PBM reform, and for addressing ‘pharmaceutical benefit manipulation’ that harms the most vulnerable in the Medicaid and Medicare programs.”
From industry trade press, to publications serving the broader business community, to media outlets relied on by government decision-makers, important story lines about pharmacy benefit manager reform continue to generate headlines and attention across the nation.
NACDS today praised the bipartisan introduction of the Protect Patient Access to Pharmacies Act (S. 2052) – a bill that would help preserve Medicare beneficiaries’ access to their pharmacy of choice and help stop “pharmaceutical benefit manipulation” that harms patients and pharmacies alike.
Organizations representing pharmacists and pharmacies are applauding the Protect Patient Access to Pharmacies Act (S. 2052) introduced on June 21 in the U.S. Senate.
NACDS is calling on North Carolina lawmakers to continue to stand up for North Carolinians in the face of “pharmaceutical benefit manipulation” in all its forms.
Action is essential component of PBM reform in the Medicaid program and vital for patients and the pharmacies serving them.
Organizations commend House Committee on Oversight and Accountability for hearing on PBM tactics.
NACDS President and CEO Steven C. Anderson released the following statement today in anticipation of a legislative markup on May 24 by the U.S. House of Representatives Committee on Energy and Commerce:
